Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-11-15

FDA Approved: PROMACTA — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for PROMACTA (eltrombopag olamine) from Novartis, resulting in updated labeling and potential expansion of the product’s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Promacta (eltrombopag)

Snippet

SUPPL AP for PROMACTA (ELTROMBOPAG OLAMINE)